Nebulizable compositions of tiotropium and formoterol
The present disclosure relates to a nebulization composition comprising tiotropium and formoterol for the treatment of inflammatory or obstructive airway disease. The present disclosure also relates to a process for preparing the composition.
1. A dual chamber container suitable for use with a nebulizer and prefilled with a nebulizable composition, comprising in one chamber a first solution of tiotropium or a pharmaceutically acceptable salt thereof and in a second chamber a second solution of formoterol or a pharmaceutically acceptable salt thereof,
wherein the first and/or second solution further comprises from about 0.1 to about 1 mg/mL of edetate disodium.
2. The dual chamber container of claim 1 , wherein the first solution comprises (a) from about 0.00125 to about 0.64 mg/mL of tiotropium bromide (equivalent to tiotropium base), (b) about 9 mg/mL sodium chloride, (c) optionally edetate disodium, (d) optionally hydrochloric acid, and (e) optionally sodium hydroxide, wherein the pH of the first solution is from about 2 to about 6, and
the second solution comprises (a) from about 0.0025 to about 0.32 mg/mL formoterol fumarate dihydrate (equivalent to formoterol fumarate), (b) about 2 to about 10 mg/mL sodium chloride, (c) optionally edetate disodium, (d) optionally hydrochloric acid, and (e) optionally sodium hydroxide, wherein the pH of the second solution is from about 4.5 to about 6.5.
3. The dual chamber container of claim 1 , wherein said nebulizable composition is substantially free of preservative.
4. The dual chamber container of claim 1 , wherein the two chambers of the dual chamber container may be separate or may be connected by a common septum.
5. The dual chamber container of claim 4 , with a common septum and a common top which when broken would provide simultaneous access to the first and second solutions.
6. The dual chamber container of claim 1 , further comprising sodium chloride in each chamber.
7. The dual chamber container of claim 1 , wherein the second solution comprises formoterol fumarate.
8. The dual chamber container of claim 7 , wherein the second solution comprises from about 0.0025 to about 0.32 mg/mL of formoterol fumarate dihydrate.
9. The dual chamber container of claim 1 , wherein the first and/or second solution further comprises from about 2 to about 10 mg/mL of sodium chloride.
10. The dual chamber container of claim 1 , wherein the first and/or second solution further comprises sodium citrate, citric acid, or any combination thereof.
11. The dual chamber container of claim 1 , wherein the first and/or second solution further comprises at least one of hydrochloric acid and sodium hydroxide.
12. The dual chamber container of claim 1 , wherein the volume of the composition is about 0.5 to about 5 mL.
13. The dual chamber container of claim 1 , wherein said composition is substantially free of preservative.
14. A method of administering tiotropium and formoterol to a patient in need thereof comprising administering to the patient by inhalation with a nebulizer a first solution of tiotropium or a pharmaceutically acceptable salt thereof and a second solution of formoterol or a pharmaceutically acceptable salt thereof, wherein the first solution has a pH of from about 2 to about 6, and the second solution has a pH of from about 4.5 to about 6.5.
15. The method of claim 14 , wherein the solutions are combined prior to inhalation.
16. The method of claim 14 , wherein the first solution comprises tiotropium bromide.
17. The method of claim 14 , wherein the first solution comprises from about 0.00125 to about 0.64 mg/mL of tiotropium bromide (equivalent to tiotropium base).
18. The method of claim 14 , wherein the second solution comprises formoterol fumarate.
19. The method of claim 14 , wherein the second solution comprises from about 0.0025 to about 0.32 mg/mL of formoterol fumarate.
20. The method of claim 14 , wherein the second solution comprises formoterol fumarate dihydrate.
21. The method of claim 20 , wherein the second solution comprises from about 0.0025 to about 0.32 mg/mL of formoterol fumarate dihydrate.
22. The method of claim 14 , wherein each of the first solution and the second solution comprises from about 2 to about 10 mg/mL of sodium chloride.
23. The method of claim 14 , wherein each of the first solution and the second solution comprises about 9 mg/mL of sodium chloride.
24. The method of claim 14 , wherein the first solution and/or the second solution further comprises sodium citrate, citric acid, or any combination thereof.
25. The method of claim 14 , wherein the first solution and/or the second solution comprises sodium citrate and citric acid.
26. The method of claim 14 , wherein the first solution and/or the second solution further comprises edetate disodium.
27. The method of claim 14 , wherein the first solution and/or the second solution further comprises hydrochloric acid, sodium hydroxide, or any combination thereof.
28. The method of claim 14 , wherein the volume of each of the first and second solutions is about 0.5 to about 5 mL.
29. A method of administering tiotropium and formoterol to a patient in need thereof comprising administering to the patient by inhalation with a nebulizer a first solution of tiotropium or a pharmaceutically acceptable salt thereof and a second solution of formoterol or a pharmaceutically acceptable salt thereof, wherein the first solution comprises about 9 mg/mL of sodium chloride and the second solution comprises about 5 mg/mL of sodium chloride.
30. A method of administering tiotropium and formoterol to a patient in need thereof comprising administering to the patient by inhalation with a nebulizer a first solution of tiotropium or a pharmaceutically acceptable salt thereof and a second solution of formoterol or a pharmaceutically acceptable salt thereof, wherein the first solution and/or the second solution comprises from about 0.001 to about 1 mg/mL of edetate disodium.